Floatz logo

Carboplatin

Squamous Cell Carcinoma of Head and Neck

AkesoSmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
81/ 100

Competitive context

249 Active assets in the Squamous Cell Carcinoma of Head and Neck cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Akeso
Phase 3BB
Irinotecan
Neonc Technologies, Inc.
Phase 2BB
Tisotumab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 2BB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →